Related Experiment Videos
Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice
Abstract:
The distribution of hexamethylmelamine (HMM), pentamethylmelamine (PMM), and their metabolites N2,N2,N4,N6-tetramethylmelamine (TMM) and N2,N4,N6-trimethylmelamine (TriMM) was investigated in different tissues of M5076/73A ovarian cancer-bearing mice given 100 mg/kg ip of either drug. The area-under-the-curve (AUC) values of HMM and PMM, expressed in microgram/g x min after these drug treatments, were 2432 and 1296 in tumor, 6290 and 8141 in liver, 9779 and 21,294 in spleen, 6840 and 10,800 in kidney, 4003 and 4295 in heart, 1569 and 1327 in brain, 163,689 and 50,809 in adipose tissue, 88,725 and 45,070 in lymph nodes, 15,033 and 18,992 in small intestine, and 393 and 351 in plasma, respectively. The elimination rate of HMM for the different organs was similar, with a half-life of 37-48 mins; PMM disappeared with more variability, the half-life being 19-46 mins. While TMM concentrations were not very different from those of HMM or PMM, TriMM was much higher in all organs evaluated, particularly the brain, where AUC values were 21-24 times those of the administered drug.
Insights
Hexamethylmelamine (HMM) and pentamethylmelamine (PMM) distribution was studied in ovarian cancer mice. TriMM, a metabolite, showed significantly higher concentrations in all organs, especially the brain.
Area of Science:
- Pharmacokinetics
- Oncology
- Drug Metabolism
Background:
- Hexamethylmelamine (HMM) and pentamethylmelamine (PMM) are antineoplastic agents.
- Understanding their distribution and metabolism is crucial for optimizing cancer therapy.
Purpose of the Study:
- To investigate the tissue distribution of HMM, PMM, and their metabolites TMM and TriMM.
- To compare the pharmacokinetic profiles of HMM and PMM in M5076/73A ovarian cancer-bearing mice.
Main Methods:
- Mice bearing M5076/73A ovarian tumors received 100 mg/kg ip of HMM or PMM.
- Tissue samples were collected, and drug and metabolite concentrations were quantified using area-under-the-curve (AUC) analysis.
Main Results:
- HMM and PMM showed variable distribution, with highest AUC values in adipose tissue and lymph nodes.
- HMM elimination half-life was 37-48 minutes; PMM half-life ranged from 19-46 minutes.
- The metabolite TriMM exhibited significantly higher concentrations than parent drugs across all tissues, particularly in the brain (21-24 times higher AUC).
Conclusions:
- TriMM is a major metabolite with extensive tissue distribution, especially in the brain.
- The distinct pharmacokinetic profiles of HMM and PMM, along with TriMM accumulation, warrant further investigation for therapeutic implications in ovarian cancer.